Shares of Personalis (PSNL) surged 5.34% in pre-market trading on Monday following a significant announcement regarding Medicare coverage for its breakthrough cancer detection technology.

The company revealed that its ultrasensitive Minimal Residual Disease (MRD) test for breast cancer has been approved for Medicare coverage. This development marks a crucial milestone for Personalis, potentially expanding the accessibility and adoption of its innovative diagnostic tool.

The Medicare coverage decision is likely driving investor optimism, as it could lead to increased revenue streams for Personalis. MRD tests are critical in cancer treatment, helping oncologists detect tiny amounts of cancer cells remaining after treatment, which can indicate the risk of recurrence. With breast cancer being one of the most common cancers worldwide, this coverage decision opens up a substantial market opportunity for Personalis.